Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Lymphoma | Research

Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens

Authors: Wei Wang, Yan Li, Haval Ali, Linjun Zhao, Di Mei, Wenqing Hu, Bin Jiang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Flow cytometry (FC) is a popular method to detect bone marrow (BM) involvement in patients with B-cell non-Hodgkin lymphoma (B-NHL). The majority of screen panels of FC still rely on finding monoclonal B-cells, e.g., B-cells with immunoglobin (Ig) light-chain restriction, which has many limitations. Therefore, exploring new markers is warranted.

Methods

A total of 52 cases of B-NHL with BM involvement were collected. The median age was 60 years. Out of these 52 cases, 34 were male, and 18 were female. A 10-color FC panel was used to detect the expression of CD54 on lymphoma cells. The expression of CD54 was calculated as the mean fluorescence index ratio (MFIR) and was described as the mean ± standard error of the mean (SEM).

Results

Up to 18/52 (34.62%) of BM specimens abnormally expressed an increased level of CD54, including 1/10 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 9/13 cases of mantle cell lymphoma (MCL), 2/14 cases of follicular lymphoma (FL), 5/9 cases of marginal zone lymphoma (MZL), and 1/3 cases of high-grade B-NHL (HG B-NHL). The expression level of CD54 was significantly increased in MCL cases (53.41 ± 11.04) compared with CLL/SLL cases (11.66 ± 2.79) and FL cases (13.49 ± 2.81). The lowest percentage of CD54-positive B-cells attained 0.13%. In 5/9 cases of MZL and 1/3 cases of HG B-NHL, increased expression of CD54 was the only abnormal immunophenotype detected besides Ig light-chain restriction. No aberrant CD54 expression was identified by FC in lymphoplasmacytic lymphoma (LPL) (0/2) and Burkitt lymphoma (BL) (0/1) cases. Aberrant expression of CD54 was not related to plasma cell differentiation.

Conclusion

Lymphoma cells, especially in MCL and MZL cases, frequently show increased expression of CD54. Such aberrant expression is not related to plasma cell differentiation. We highly recommend adding CD54 to the FC screening panel to detect BM involvement in patients with B-NHL.

Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65. https://doi.org/10.1182/blood-2003-12-4434.CrossRefPubMed

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61. https://doi.org/10.1182/blood-2006-08-038257.CrossRefPubMed

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42. https://doi.org/10.1182/blood-2013-09-524108.CrossRefPubMedPubMedCentral

Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017;130:1409–17. https://doi.org/10.1182/blood-2017-03-771915.CrossRefPubMed

Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132:49–58. https://doi.org/10.1182/blood-2017-11-816405.CrossRefPubMedPubMedCentral

Mancuso P, Calleri A, Antoniotti P, Quarna J, Pruneri G, Bertolini F. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010;10:644. https://doi.org/10.1186/1471-2407-10-644.CrossRefPubMedPubMedCentral

Merli M, Arcaini L, Boveri E, Rattotti S, Picone C, Passamonti F, et al. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. Eur J Haematol. 2010;85:405–15. https://doi.org/10.1111/j.1600-0609.2010.01503.x.CrossRefPubMed

Arima H, Maruoka H, Nasu K, Tabata S, Kurata M, Matsushita A, et al. Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:2645–53. https://doi.org/10.3109/10428194.2013.788697.CrossRefPubMed

Kim B, Lee ST, Kim HJ, Kim SH. Bone marrow flow cytometry in staging of patients with B-cell non-Hodgkin lymphoma. Ann Lab Med. 2015;35:187–93. https://doi.org/10.3343/alm.2015.35.2.187.CrossRefPubMedPubMedCentral

10.

Greenbaum U, Levi I, Madmoni O, Lior Y, Al-Athamen K, Perry ZH, et al. The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry. Leuk Lymphoma. 2019;60:2477–82. https://doi.org/10.1080/10428194.2019.1587755.CrossRefPubMed

11.

Martin-Moro F, Piris-Villaespesa M, Marquet-Palomanes J, Garcia-Cosio M, Villarrubia J, Lario A, et al. Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology. Cytometry B Clin Cytom. 2020;98:525–8. https://doi.org/10.1002/cyto.b.21863.CrossRefPubMed

12.

Statuto T, Valvano L, Calice G, Villani O, Pietrantuono G, Mansueto G, et al. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. Leuk Res. 2020;88:106267. https://doi.org/10.1016/j.leukres.2019.106267.CrossRefPubMed

13.

Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood. 1998;91:1864–72.CrossRef

14.

Saxena A, Moshynska O, Kanthan R, Bhutani M, Maksymiuk AW, Lukie BE. Distinct B-cell clonal bands in helicobacter pylori gastritis with lymphoid hyperplasia. J Pathol. 2000;190:47–54. https://doi.org/10.1002/(SICI)1096-9896(200001)190:1<47::AID-PATH506>3.0.CO;2-O.

15.

Attygalle AD, Liu H, Shirali S, Diss TC, Loddenkemper C, Stein H, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104:3343–8. https://doi.org/10.1182/blood-2004-01-0385.CrossRefPubMed

16.

Kussick SJ, Kalnoski M, Braziel RM, Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol. 2004;121:464–72. https://doi.org/10.1309/4EJ8-T3R2-ERKQ-61WH.CrossRefPubMed

17.

Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24:512–20. https://doi.org/10.1038/leu.2009.287.CrossRefPubMedPubMedCentral

18.

Pillai RK, Surti U, Swerdlow SH. Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies. Haematologica. 2013;98:1571–80. https://doi.org/10.3324/haematol.2013.085506.CrossRefPubMedPubMedCentral

19.

Kaleem Z, Zehnbauer BA, White G, Zutter MM. Lack of expression of surface immunoglobulin light chains in B-cell non-Hodgkin lymphomas. Am J Clin Pathol. 2000;113:399–405. https://doi.org/10.1309/28ED-MM0T-DT3B-MT4P.CrossRefPubMed

20.

Li S, Eshleman JR, Borowitz MJ. Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma. Am J Clin Pathol. 2002;118:229–34. https://doi.org/10.1309/57G0-1BNF-KB9R-L4HN.CrossRefPubMed

21.

van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med (Berl). 1996;74:13–33. https://doi.org/10.1007/BF00202069.CrossRef

22.

Kuhlman P, Moy VT, Lollo BA, Brian AA. The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. Contributions of adhesion and co-activation. J Immunol. 1991;146:1773–82.PubMed

23.

Boyd AW, Wawryk SO, Burns GF, Fecondo JV. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci U S A. 1988;85:3095–9. https://doi.org/10.1073/pnas.85.9.3095.CrossRefPubMedPubMedCentral

24.

Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med. 1988;167:1811–24. https://doi.org/10.1084/jem.167.6.1811.CrossRefPubMed

25.

Wang W, Li Y, Rivera Rivera X, Zhao L, Mei D, Hu W, et al. Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma. BMC Cancer. 2021;21:1011. https://doi.org/10.1186/s12885-021-08753-0.CrossRefPubMedPubMedCentral

26.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. https://doi.org/10.1182/blood-2016-01-643569.CrossRefPubMedPubMedCentral

27.

Swerdlow SHCEHN, Jaffe ES, Pileri SA, Stein H, Thiele J, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.

28.

Gorczyca W. Flow Cytometry in neoplastic hematology: morphologic-Immunophenotypic correlation. New York: CRC Press; 2017.CrossRef

29.

Foucar KRK, Czuchlewski D. Bone marrow pathology. 3rd ed. Chicago: American Society for Clinical Pathology Press; 2010.

30.

Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011;187:3931–41. https://doi.org/10.4049/jimmunol.1101230.CrossRefPubMed

31.

Schmidt B, Kremer M, Gotze K, John K, Peschel C, Hofler H, et al. Bone marrow involvement in follicular lymphoma: comparison of histology and flow cytometry as staging procedures. Leuk Lymphoma. 2006;47:1857–62. https://doi.org/10.1080/10428190600709127.CrossRefPubMed

32.

Talaulikar D, Shadbolt B, Dahlstrom JE, McDonald A. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the international prognostic index (IPI). J Hematol Oncol. 2009;2:49. https://doi.org/10.1186/1756-8722-2-49.CrossRefPubMedPubMedCentral

33.

van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–75. https://doi.org/10.1038/leu.2012.120.CrossRefPubMedPubMedCentral

34.

Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. Cytometry B Clin Cytom. 2015;88:253–60. https://doi.org/10.1002/cyto.b.21233.CrossRefPubMed

35.

Rajab A, Axler O, Leung J, Wozniak M, Porwit A. Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population. Int J Lab Hematol. 2017;39(Suppl 1):76–85. https://doi.org/10.1111/ijlh.12678.CrossRefPubMed

36.

Hedley BD, Keeney M, Popma J, Chin-Yee I. Novel lymphocyte screening tube using dried monoclonal antibody reagents. Cytometry B Clin Cytom. 2015;88:361–70. https://doi.org/10.1002/cyto.b.21251.CrossRefPubMed

37.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study. Leukemia. 2016;30:929–36. https://doi.org/10.1038/leu.2015.313.CrossRefPubMedPubMedCentral

38.

Chovancova J, Bernard T, Stehlikova O, Salek D, Janikova A, Mayer J, et al. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach. Cytometry B Clin Cytom. 2015;88:92–100. https://doi.org/10.1002/cyto.b.21210.CrossRefPubMed

39.

Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101:336–45. https://doi.org/10.3324/haematol.2015.134957.CrossRefPubMedPubMedCentral

40.

Sorigue M, Canamero E, Miljkovic MD. Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. Blood Rev. 2021;47:100778. https://doi.org/10.1016/j.blre.2020.100778.CrossRefPubMed

41.

Schniederjan SD, Li S, Saxe DF, Lechowicz MJ, Lee KL, Terry PD, et al. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. Am J Clin Pathol. 2010;133:718–26. https://doi.org/10.1309/AJCP0XQDGKFR0HTW.CrossRefPubMed

Title: Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens
Authors: Wei Wang
Yan Li
Haval Ali
Linjun Zhao
Di Mei
Wenqing Hu
Bin Jiang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lymphoma
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-09061-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study

ERK3 is transcriptionally upregulated by ∆Np63α and mediates the role of ∆Np63α in suppressing cell migration in non-melanoma skin cancers

Capsular extension at ultrasound is associated with lateral lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study

High-intensity interval training in breast cancer survivors: a systematic review

Knowledge, attitudes, and practice of cervical cancer prevention among health workers in rural health centres of Northern Uganda

Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer